Business
Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update
PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis and PORTOLA Phase 2a clinical trial evaluating zetomipzomib in autoimmune
About this update from Kezar Life Sciences, Inc.
[{"type":"text","content":"\n\nPALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis and PORTOLA Phase 2a clinical trial evaluating zetomipzomib in autoimmune hepatitis are both open for enrollment\n\n\n\nKZR-261 dose escalation study continues to progress and display a favorable safety and tolerability profile\n\n\n\nCash, cash equivalents and marketable securities totaled $236.6 million as of June 30, 2023\n\n\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nKezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.\n\n\n“This quarter, we’ve been laser-focused on executing on our three ongoing clinical trials to validate the broad potential of our product candidates,” said John Fowler, Kezar’s Co-Founder and Chief Executive Officer. “Now actively recruiting patients, our PALIZADE and PORTOLA clinical trials are designed to demonstrate zetomipzomib’s potential to be a steroid-sparing, immunomodulating treatment for multiple autoimmune conditions. Our first-in-class protein secretion inhibitor, KZR-261, continues to demonstrate a favorable safety and tolerability profile as we proceed with our dose-escalation study, and represents only the first of several potential assets generated by our Sec61 translocon inhibition platform. I commend the Kezar team for their hard work and unwavering commitment to our mission of delivering novel treatments to patients fighting difficult-to-treat chronic diseases.”\n\n\nZetomipzomib: Selective Immunoproteasome Inhibitor\n\n\nPALIZADE – Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis (LN) (ClinicalTrials.gov: NCT05781750)\n\n\n\nPALIZADE is a global, placebo-controlled, randomized, double-blind Phase 2b clinical trial evaluating the efficacy and safety of two dose-levels of zetomipzomib in patients with active LN. Target enrollment will be 279 patients, randomly assigned (1:1:1) to receive 30 mg of zetomipzomib, 60 mg of zetomipzomib or placebo subcutaneously once weekly for 52 weeks, in addition to standard background therapy. Background therapy can, but will not be mandated to, include standard induction therapy. Over the initial 16 wee...